FDCC
GSK icon

Foster Dykema Cabot & Co’s GSK GSK Stock Holding History

Foster Dykema Cabot & Co’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$42K Hold
1,160
– – 0.01% 171
2023
Q2 		$41K Hold
1,160
– – ﹤0.01% 175
2023
Q1 		$41K Buy
+1,160
New +$40.6K 0.01% 150

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Foster Dykema Cabot & Co's GSK Position: Q3 2023 in Review

Foster Dykema Cabot & Co held its GSK (GSK) position steady in Q3 2023 at 1,160 shares worth $42K. The position accounts for 0.01% of the portfolio, ranked #171.

Foster Dykema Cabot & Co first reported a position in GSK in Q1 2023 and has held it in 3 quarters since. 846 funds tracked by Wall St. Rank hold GSK as of Q3 2023.

  • Foster Dykema Cabot & Co held 1,160 shares of GSK worth $42K as of Q3 2023.
  • Foster Dykema Cabot & Co left its GSK share count unchanged in Q3 2023.
  • GSK made up 0.01% of Foster Dykema Cabot & Co's portfolio in Q3 2023, its #171 holding.
  • Foster Dykema Cabot & Co first reported a position in GSK in Q1 2023 and has held it in 3 quarters since.
  • 846 funds tracked by Wall St. Rank held GSK as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.